China's demand for Cold and Flu Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2013, 2018 and 2023) and long-term forecasts through 2028 and 2033 are presented. Major producers in China are profiled.China's demand for Cold and Flu Drugs will continue to grow at 8% by 2033.
The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews are conducted with Chinese industry experts, university professors, and producers in China. Economic models and quantitative methods are applied in this report to project market demand and industry trends. Metric system is used and values are presented in either Yuan (RMB, current price) and/or US dollars.
Table of Contents
INTRODUCTION
BUSINESS ENVIRONMENT
COLD AND FLU DRUGS INDUSTRY ASSESSMENTS
COLD AND FLU DRUGS PRODUCTION AND DEMAND
COLD AND FLU DRUGS MARKET OUTLOOK
MARKETING STRATEGIES
VII.COLD AND FLU DRUGS PRODUCER DIRECTORY
INTRODUCTION
BUSINESS ENVIRONMENT
III.COLD AND FLU DRUGS INDUSTRY ASSESSMENTS
COLD AND FLU DRUGS PRODUCTION AND DEMAND
COLD AND FLU DRUGS MARKET OUTLOOK
INTRODUCTION
BUSINESS ENVIRONMENT
III. COLD AND FLU DRUGS INDUSTRY ASSESSMENTS
COLD AND FLU DRUGS PRODUCTION AND DEMAND
MARKETING STRATEGIES
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Changchun Haiwai Medicine Co., Ltd
- China Maoxiang Group